DeltaNu Wins Prestigious R&D 100 Award
News Sep 27, 2005
DeltaNu has announced that it has won a prestigious R&D 100 award for 2005.
R&D 100 awards are the “Oscars of Invention” according to the Chicago Tribune.
DeltaNu manufactures spectrometers for chemical analysis. A product released earlier this year is the Investigator which is used to follow high speed chemical reactions that are accelerated by microwaves.
Chemical reactions that take hours by traditional heating methods take place in seconds in a microwave reactor.
The primary market for these reactors is drug discovery, where large pharmaceutical companies want to develop drugs as rapidly as possible.
One of the problems microwave assisted synthesis faces is that reactions occur so rapidly that traditional chemical analysis techniques are unable to follow the extent of a chemical reaction.
To solve this problem DeltaNu developed a spectrometer that can look inside the microwave reactor and determine the concentration of the reactants and products of a reaction as it is taking place.
“This innovation is far more sophisticated than the microwave reactors themselves”, Keith Carron, CEO of DeltaNu states.
“The project took a little over a year to complete by our technical team, and Carron recently installed the first system at one of the worlds largest drug manufactures, AstraZenaca.”
DeltaNu is working with CEM Corporation in Mathews, North Carolina to sell embedded systems in CEM’s microwave reactors.
“We are very gratified to win such a prestigious award”, said Rick Cox, VP Sales and Marketing for DeltaNu.
“Our core technology and emphasis is Raman spectroscopy, and our R&D team is the engine that drives DeltaNu products to niche markets.”
“This further substantiates that they are one of the most innovative group of engineers and chemists in their field”.
“DeltaNu is a great example of the kind of technology business we are trying to develop in Wyoming,” said Wyoming Business Council Chief Operating officer Bob Jensen.
“The Business Council is happy to have been able to help in the growth of DeltaNu.’
“These kinds of technology-based jobs are what we and the university is striving to help generate.”
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE